A conserved pan-cancer transcriptional signature identifies human M-MDSCs and reveals a REL/NFKB1⁺ rMos immunosuppressive population
This study establishes a conserved five-gene transcriptional signature to reliably identify human monocytic myeloid-derived suppressor cells (M-MDSCs) across multiple cancers, revealing a distinct, NF-κB-regulated REL/NFKB1⁺ rMos subset characterized by SPP1 expression that correlates with immune suppression and poor patient survival.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Cancer is not just a disease of rogue cells multiplying; it is also a story of a body's own defense system being tricked into silence. Inside tumors, a special group of immune cells called myeloid-derived suppressor cells acts as a shield for the cancer. These cells, particularly a type known as monocytic myeloid-derived suppressor cells, are experts at shutting down the T-cells that would normally hunt and destroy the tumor. For decades, scientists have struggled to find these cells in human patients. They are like chameleons, wearing the same camouflage as other healthy immune cells, making them nearly impossible to spot with standard tests. Without a reliable way to identify them, researchers cannot fully understand how they help cancer grow or how to stop them.
A team of researchers has now found a new way to track these elusive cells across many different types of cancer. By combining computer analysis of genetic data with careful examination of human tissue samples, they discovered a specific set of five genetic markers that act as a unique fingerprint for these suppressor cells. This discovery allows scientists to find these cells in breast, lung, colorectal, and other cancers with much greater precision. More importantly, the study revealed a hidden subgroup within these cells that is particularly dangerous. These cells, which the researchers call "rMos," are driven by a specific internal switch involving two proteins, REL and NFKB1, and they produce high levels of a substance called SPP1 that helps tumors spread and resist treatment.
The journey to this discovery began with a simple but difficult question: how do you find a needle in a haystack when the needle looks exactly like the hay? The researchers started by looking at genetic data from breast cancer patients. They compared the genes active in the suspected suppressor cells against those in normal immune cells to see what made the suppressors unique. This computer-based search pointed to five specific genes: VCAN, APOBEC3A, CD300E, EREG, and FCN1. To ensure these genes were not just a fluke of breast cancer, the team tested them in tissue samples from six different types of human cancer, including lung, colorectal, and kidney cancers. Using a technique that allows multiple colors to be seen on a single slide, they confirmed that the proteins produced by these five genes were indeed present in the cells that looked like suppressors under a microscope. This confirmed that the genetic signature works across a wide range of human tumors, providing a reliable map to find these cells.
Once the team could reliably identify the suppressor cells, they looked closer to see if there were different types hiding within the group. They used high-resolution genetic mapping to break down the population of these cells into smaller, more distinct groups. In doing so, they found a specific subset of cells that matched a profile previously seen only in mice. These cells, which the researchers named rMos, are defined by the presence of a protein called CCR2 and the activity of a protein called c-Rel. The study showed that these rMos exist in human tumors just as they do in mice, appearing in samples from colorectal cancer, lung cancer, and melanoma. The researchers also found that in human rMos, the c-Rel protein works closely with another protein called NFKB1, suggesting they team up to control the cell's behavior.
The most significant finding emerged when the researchers focused on lung adenocarcinoma, a common form of lung cancer. They compared the rMos found in healthy lung tissue with those found inside tumors and discovered a dramatic change. The tumor-associated rMos had completely rewired their genetic instructions. They stopped producing some normal signals and started producing massive amounts of SPP1, a protein known to help tumors grow, spread to other parts of the body, and block the immune system. The researchers checked large databases of patient records and found a clear link: patients with higher levels of SPP1 in their tumors tended to have shorter survival times. This suggests that these specific rMos, with their high SPP1 output, are likely a major reason why some lung cancers are so aggressive and hard to treat.
This work does not claim to have solved the problem of cancer, but it provides a powerful new tool for understanding it. The researchers have established a molecular framework that can identify these suppressor cells in humans, something that was previously very difficult. They have also highlighted a specific, dangerous subgroup of these cells that uses a unique genetic switch and produces a harmful protein. While the study confirms the presence of these cells and their genetic traits, the exact mechanisms of how they suppress the immune system and how they might be targeted for therapy still need to be tested in the lab. However, by naming these cells and defining their genetic signature, the study offers a clear path forward for scientists to design new treatments that could potentially turn off these suppressors and let the body's natural defenses fight the cancer again.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.